Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

How I invested my first £1,000 in FTSE shares… and the mistakes I made

It can be intimidating investing for the very first time. Here, I share my first £1,000 investment and what mistakes…

Read more »

Mature couple in a discussion while eating a meal in a restaurant.
Investing Articles

How to invest £290 a month in UK shares for an income that aims to beat the State Pension

UK shares can offer a lucrative path for investors seeking a retirement income stream that beats the State Pension. Zaven…

Read more »

Aviva logo on glass meeting room door
Investing Articles

Aviva’s share price has left rivals in the dust. Here’s why it’s still good value

Mark Hartley explains why he feels his Aviva shares continue to offer excellent value even after five years of rapid…

Read more »

Investing Articles

2 excellent investment trusts to consider for an ISA or SIPP

This pair of investment trusts would offer a SIPP or ISA exposure to what could be a very large global…

Read more »

Tree lined "tunnel" in the English countryside of West Sussex in autumn
Investing Articles

How much is needed in an ISA to target a £3,150 monthly passive income?

Ben McPoland explains why it's not pie in the sky to aim for chunky ISA passive income, and also highlights…

Read more »

UK money in a Jar on a background
Investing Articles

Got a spare £3 a day? Here’s the passive income you could earn from it!

A few pounds a day might not seem like much. But, as our writer explains, it could help generate hundreds…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

Here’s how a small dividend stock ISA could produce £1,400 in passive income a year

Investing in dividend stocks can be a great way to generate a second income. And if they're held in an…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Here’s how Barclays shares could climb another 40%

Stock markets are clouded by geopolitical threats at the moment, but Barclays' shares could be heading for a further upwards…

Read more »